Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Inclusion Criteria:

   - Immunophenotypically confirmed diagnosis of follicular lymphoma (FL),
   Immunophenotypically confirmed diagnosis of Large B Cell Lymphoma (LBCL) (including
   transformed FL and Primary Mediastinal B-cell Lymphoma) OR Immunophenotypically
   confirmed diagnosis of mantle cell lymphoma (MCL) undergoing commercially approved
   CAR-T therapy in accordance with FDA indication with enrollment in this trial prior to
   CAR infusion

   - CAR-T product must meet manufacturer specifications

   - PET measurable disease at the time a decision is made to prescribe CAR treatment

   - Has sample from diagnosis or relapse available for genomic DNA extraction to identify
   patient's clonotype via clonoSEQ (see lab manual for details)

Exclusion Criteria:

   - Lack of archival diagnostic or fresh/archival relapse tissue for purposes of
   determining patient's lymphoma clonotype. Given that 5-10% of patients cannot have a
   clonotype identified by clonoSEQ, those patients will be removed from the study and
   excluded from analysis, but their samples will continued to be stored for future
   analysis as improvements to the analysis platform are made.

   - No patients are to be excluded on the basis of gender, race, ethnic background, sexual
   orientation, or other demographic characteristics.